Dabigatran for the prevention and treatment of thromboembolic disorders.

about

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.Dabigatran-Induced Massive Spontaneous Hemothorax.

P2860

Q33823354-4BB15215-E877-4779-8155-E028C22CA543 Q42141808-DE1C67E8-FC6D-43EC-B7A4-AE21B690A452

P2860

Dabigatran for the prevention and treatment of thromboembolic disorders.

Item

http://www.wikidata.org/entity/Q38406325

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dabigatran for the prevention and treatment of thromboembolic disorders.

@en

type

Item

label

Dabigatran for the prevention and treatment of thromboembolic disorders.

@en

prefLabel

Dabigatran for the prevention and treatment of thromboembolic disorders.

@en

P1476

Dabigatran for the prevention and treatment of thromboembolic disorders.

@en

P2093

Adrian Baranchuk

http://www.w3.org/2001/XMLSchema#string

Andres Enriquez

http://www.w3.org/2001/XMLSchema#string

Christopher Simpson

http://www.w3.org/2001/XMLSchema#string

Damian Redfearn

http://www.w3.org/2001/XMLSchema#string

Hoshiar Abdollah

http://www.w3.org/2001/XMLSchema#string

Kevin Michael

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

Safety of new oral anticoagulant drugs: a perspective

A specific antidote for dabigatran: functional and structural characterization

Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

P304

529-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2015.1034692

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274571531

http://www.w3.org/2001/XMLSchema#string

P698

25843430

http://www.w3.org/2001/XMLSchema#string

P921

thromboembolism

Dabigatran for the prevention and treatment of thromboembolic disorders.

about

P2860

P2860

Dabigatran for the prevention and treatment of thromboembolic disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921